Study of Vitamin D Supplementation to Male HIV Sero-positive Patients

• Status: Completed
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: Male

Summary

The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets):

1. Calcium

2. Calcium and 25-hydroxy-vitamin D

3. Calcium and 25-hydroxy-vitamin D and 1,25-dihydroxyvitamin D

The endpoints are:

• Serum vitamin D

• Parathyroid hormone

• ionized calcium

• T-lymphocyte fractions (naïve, mature, Tregs)

• Osteocalcin (bone metabolism)

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Hvidovre University Hospital
• Treatments: Calcitriol; Calcium; Calcium, Dietary; Ergocalciferols; Vitamin D; Vitamins

Criteria

Inclusion Criteria:

• male

• HIV-positive

• at least 18 years old

• receiving HiglyActiveAntiRetroviral Therapy (HAART)

Exclusion Criteria:

• hypercalcemia

• tuberculosis

• osteoporosis or other bone disease

• cancer with bone metastasis